Private Equity

Consuelo Vanderbilt Costin's recurring role at the elite Forbes Iconoclast Summit is no social engagement. It's a masterclass in converting legacy into currency.

A new partnership aims to scale AI-generated software. We analyze the tech, security, and market impact of this move to redefine enterprise development.

Australian firm Taurus Management Group is opening the exclusive world of IPOs to independent investors, but does "democratization" come with a catch?

A recent FDA approval for a generic cancer drug adds to a growing market, revealing the strategic alliances redefining healthcare access.

Fresh off its IPO, Bill Ackman's firm is ditching the exclusive call for open X Spaces Q&As. A signal of radical transparency or a new compliance risk?

As corporate interests reshape medicine, a leading physician's call for stewardship revives a debate on the soul of healthcare. Can timeless values survive?

Ontra elevates its first finance hire, Andy Lujan, to CFO. A look at how his nine-year journey and military discipline will steer the AI leader's next chapter.

A call for research on vaccine side effects exposes a deeper crisis: the collapse of public trust in science. Can rigorous data heal a polarized nation?

Bluejay Diagnostics secures critical funding to advance its rapid sepsis test, extending its cash runway but raising questions about shareholder dilution.

Stonegate Capital's updated coverage validates AB Science's pivot to ALS and AML, but can its promising clinical assets and shrewd financing de-risk the path forward?

A press release announced a bright new chapter for DBH. The real story? A $280M debt default, a lender takeover, and a new CEO's daunting mission.

Trillium's sale of its nuclear valve unit to Framatome isn't just a divestment; it's a strategic realignment reshaping the critical infrastructure landscape.

The tech-forward wealth platform is integrating alternative assets, margin, and options, challenging legacy players and democratizing access to elite strategies.

Optiv's sale of its consulting arm to Vobis Ventures isn't just a deal; it's a strategic bet on specialization in the new era of autonomous AI governance.

A strategic investment in AxisCare signals a major shift as private equity fuels AI's move from the data center to the living room, reshaping elder care.

QuadReal's appointment of Deloitte veteran Trevor Nakka signals a strategic pivot, adding elite financial governance to its $98.5B portfolio to fuel a disciplined global expansion.

As AI and cyber risks escalate, the new 'Chief Trust Officer' role is emerging. HITRUST's appointment of a veteran leader signals a major shift for all.

Frazier Healthcare Partners adds Milton Boyer as an EIR, signaling a strategic push into the complex pharmaceutical manufacturing sector with a proven operator.

With a $1.25 billion investment from Apollo Funds, McKesson is spinning off its medical supply unit. Is this a cure for corporate bloat or a new symptom of financialization in healthcare?

Pluri is moving its advanced cell-expansion tech from the lab to the lucrative U.S. aesthetics market. Is this a savvy commercial pivot or a risky gamble?